Skip to main content

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit.

JMP Securities Hematology and Oncology Summit
Fireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET
Location: Virtual

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.67
-5.44 (-2.59%)
AAPL  266.85
+2.27 (0.86%)
AMD  196.74
-3.41 (-1.71%)
BAC  51.36
-1.70 (-3.20%)
GOOG  314.38
-0.52 (-0.17%)
META  646.25
-9.40 (-1.43%)
MSFT  388.42
-8.81 (-2.22%)
NVDA  190.98
+1.16 (0.61%)
ORCL  140.79
-7.29 (-4.92%)
TSLA  402.36
-9.46 (-2.30%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.